Trials / Conditions / Solid Tumors, Adult

Solid Tumors, Adult

23 registered clinical trials studyying Solid Tumors, Adult — 14 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor NCT07396584	Hutchmed	Phase 1 / Phase 2
Recruiting	A Phase I/II Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 ) NCT07417189	Abbisko Therapeutics Co, Ltd	Phase 1 / Phase 2
Not Yet Recruiting	A Study of GC203 TIL in Advanced Solid Tumors (NF) NCT07256756	Shanghai Juncell Therapeutics	Phase 1
Recruiting	A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors NCT07228247	Hutchmed	Phase 1 / Phase 2
Not Yet Recruiting	Granzyme B-targeted PET Imaging Monitoring Tumor Responses to Immunotherapy NCT06916442	Zhongnan Hospital	—
Recruiting	Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid Tumors NCT06504368	Dicerna Pharmaceuticals, Inc., a Novo Nordisk company	Phase 1
Recruiting	PANK-003 Cell Injection Combined with Standard Adjuvant Chemotherapy After Surgery in Patients with Solid Tumo NCT06897228	Shenzhen Celconta Life Science Co., Ltd.	Phase 1
Recruiting	HF158K1 in Patients With HER-2 Expressing Advanced Solid Tumors NCT05861895	HighField Biopharmaceuticals Corporation	Phase 1
Recruiting	Low-dose Chemotherapy Under Hypoglycaemia for the Treatment of Relapsed Refractory Advanced Solid Tumours NCT06404528	Wuxi People's Hospital	N/A
Recruiting	Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors NCT05887492	Tango Therapeutics, Inc.	Phase 1 / Phase 2
Unknown	A Clinical Study on the Efficacy and Mechanism of Tumor Treatment Vaccine (TTV) for Recurrent and Refractory A NCT05747339	Wuxi People's Hospital	N/A
Recruiting	First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Particip NCT05768139	Eli Lilly and Company	Phase 1 / Phase 2
Terminated	Study of VP301 in Patients With Multiple Myeloma, Lymphoma, or Solid Tumors NCT05698888	Virtuoso BINco, Inc.	Phase 1
Withdrawn	Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcino NCT05472220	Pamela Munster	Phase 1
Recruiting	GT101 Injection for the Treatment of Metastatic or Recurrent Solid Tumors NCT05430373	Grit Biotechnology	Phase 1
Active Not Recruiting	NECVAX-NEO1 in Addition to Checkpoint Inhibitor in Patients With Solid Tumors NCT05354323	NEC OncoImmunity AS	Phase 1
Terminated	Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors NCT05228015	Ikena Oncology	Phase 1
Completed	Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors NCT05018273	Nykode Therapeutics ASA	Phase 1
Unknown	Study of ON 123300 in Patients With Advanced Cancer NCT04739293	Traws Pharma, Inc.	Phase 1
Recruiting	TIL Injection for the Treatment of Metastatic or Recurrent Solid Tumors NCT06088472	Grit Biotechnology	Phase 1
Recruiting	Imaging of Solid Tumors Using FAP-2286 NCT04621435	Thomas Hope	Phase 1
Completed	A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors NCT04587479	Jacobio Pharmaceuticals Co., Ltd.	Phase 1
Terminated	A Clinical Study to Evaluate CAR-T Cell-based Medicinal Product in the Treatment of Advanced Solid Tumors NCT04467853	Shanghai East Hospital	Phase 1